GGrantIndex
← Leaderboards

Mahesh P Gupta

University Of Chicago

$12,529,486
Attributed
$12,529,486
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $965.7K · FY200521
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21

Funding mix

By agency

NIH$12,529,486 · 7

By mechanism

R01$12,529,486 · 7

Top collaborators

No co-investigators on record.

Most similar at University Of Chicago

Same institution · by research overlap

Others in their field

Top investigators on “Heart Failure

Research focus

Heart FailureBaseHeartCell GrowthCardiacSirtuinsLongevityLaboratoriesFibrosisOxidative StressTransgenic MiceSignal TransductionHeart HypertrophyResponseMediatingCell NucleusCellsMitochondriaProtein IsoformsCardiac MyocytesNovel TherapeuticsEnzymesBiological ProcessMyocardium

Grant awards (29)

Exploring roles of sirtuins in protecting diabetic hearts$468,268
R01 · FY2021 · HL · contact PI
Improving post-surgery recovery of failing hearts by targeting cardiomyocyte senescence$430,115
R01 · FY2021 · HL · contact PI
Exploring roles of sirtuins in protecting diabetic hearts$468,268
R01 · FY2020 · HL · contact PI
Improving post-surgery recovery of failing hearts by targeting cardiomyocyte senescence$430,115
R01 · FY2020 · HL · contact PI
Exploring roles of sirtuins in protecting diabetic hearts$469,431
R01 · FY2019 · HL · contact PI
Improving post-surgery recovery of failing hearts by targeting cardiomyocyte senescence$430,115
R01 · FY2019 · HL · contact PI
Exploring roles of sirtuins in protecting diabetic hearts$482,604
R01 · FY2018 · HL · contact PI
Improving post-surgery recovery of failing hearts by targeting cardiomyocyte senescence$430,115
R01 · FY2018 · HL · contact PI
Blocking cardiac toxicity of anticancer drugs$448,023
R01 · FY2016 · HL · contact PI
Activation of sirtuins to prevent adverse cardiac remodeling after CABG$395,000
R01 · FY2016 · HL · contact PI
Blocking cardiac toxicity of anticancer drugs$441,129
R01 · FY2015 · HL · contact PI
Activation of sirtuins to prevent adverse cardiac remodeling after CABG$389,075
R01 · FY2015 · HL · contact PI
Blocking cardiac toxicity of anticancer drugs$439,139
R01 · FY2014 · HL · contact PI
Activation of sirtuins to prevent adverse cardiac remodeling after CABG$387,100
R01 · FY2014 · HL · contact PI
Blocking cardiac toxicity of anticancer drugs$426,031
R01 · FY2013 · HL · contact PI
Activation of sirtuins to prevent adverse cardiac remodeling after CABG$395,000
R01 · FY2013 · HL · contact PI
The Role of PARP-SIR2 Signaling in Heart Failure$486,915
R01 · FY2011 · HL · contact PI
The Role of PARP-SIR2 Signaling in Heart Failure$491,959
R01 · FY2010 · HL · contact PI
The Role of PARP-SIR2 Signaling in Heart Failure$502,804
R01 · FY2009 · HL · contact PI
The Role of PARP-SIR2 Signaling in Heart Failure$528,123
R01 · FY2008 · HL · contact PI
Histone deacetylases in pathogenesis of heart failure$537,722
R01 · FY2007 · HL · contact PI
The Role of PARP-SIR2 Signaling in Heart Failure$427,954
R01 · FY2007 · HL · contact PI
Histone deacetylases in pathogenesis of heart failure$548,207
R01 · FY2006 · HL · contact PI
Histone deacetylases in pathogenesis of heart failure$452,715
R01 · FY2005 · HL
Histone deacetylases in pathogenesis of heart failure$439,529
R01 · FY2004 · HL
Alpha-Myosin Heavy Chain Gene Repression &Heart Failure$278,030
R01 · FY2004 · HL
Alpha-Myosin Heavy Chain Gene Repression &Heart Failure$302,000
R01 · FY2003 · HL
Alpha-Myosin Heavy Chain Gene Repression &Heart Failure$302,000
R01 · FY2002 · HL
Alpha-Myosin Heavy Chain Gene Repression &Heart Failure$302,000
R01 · FY2001 · HL